Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Tumor-Agnostic 1

Conditions

Glioblastoma 2Recurrence 1Glioma 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 46Radiosurgery 34Cyclophosphamide 28Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16fludarabine 14X-Rays 13Ipilimumab 13Surgical Procedures, Operative 12Lomustine 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11dinutuximab 10trametinib 9abemaciclib 9AZD 6244 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
AZD1390 × CNS × 90 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

NCT05182905 2026-03-09

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Active not recruiting
97 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡